B-intervention	0	6	Weight
I-intervention	7	14	Lifting
O	15	18	and
B-condition	19	27	Physical
I-condition	28	36	Function
O	37	42	Among
O	43	52	Survivors
O	53	55	of
O	56	62	Breast
O	63	69	Cancer
O	69	70	:
O	71	72	A
O	73	77	Post
O	78	81	Hoc
O	82	90	Analysis
O	91	93	of
O	94	95	a
O	96	106	Randomized
O	107	117	Controlled
O	118	123	Trial
O	123	124	.

O	125	134	Survivors
O	135	137	of
O	138	144	breast
O	145	151	cancer
O	152	155	may
O	156	166	experience
O	167	180	deterioration
O	181	183	of
O	184	192	physical
O	193	201	function
O	201	202	.

O	203	207	This
O	208	210	is
O	211	220	important
O	221	228	because
O	229	233	poor
O	234	242	physical
O	243	251	function
O	252	255	may
O	256	258	be
O	259	269	associated
O	270	274	with
O	275	284	premature
O	285	294	mortality
O	294	295	,
O	296	305	injurious
O	306	311	falls
O	311	312	,
O	313	317	bone
O	318	326	fracture
O	326	327	,
O	328	331	and
O	332	342	disability
O	342	343	.

O	344	346	We
O	347	356	conducted
O	357	358	a
O	359	363	post
O	364	367	hoc
O	368	376	analysis
O	377	379	to
O	380	387	explore
O	388	391	the
O	392	401	potential
O	402	410	efficacy
O	411	413	of
O	414	420	slowly
O	421	432	progressive
O	433	439	weight
O	440	447	lifting
O	448	450	to
O	451	457	reduce
O	458	461	the
O	462	471	incidence
O	472	474	of
O	475	483	physical
O	484	492	function
O	493	506	deterioration
O	507	512	among
O	513	522	survivors
O	523	525	of
O	526	532	breast
O	533	539	cancer
O	539	540	.

O	541	548	Between
O	549	556	October
O	557	561	2005
O	562	565	and
O	566	572	August
O	573	577	2008
O	577	578	,
O	579	581	we
O	582	591	conducted
O	592	593	a
O	594	600	single
O	600	601	-
O	601	606	blind
O	606	607	,
O	608	610	12
O	610	611	-
O	611	616	month
O	616	617	,
O	618	628	randomized
O	629	639	controlled
O	640	645	trial
O	646	648	of
O	649	654	twice
O	654	655	-
O	655	658	per
O	658	659	-
O	659	663	week
O	664	670	slowly
O	671	682	progressive
O	683	689	weight
O	690	697	lifting
O	698	700	or
B-control	701	709	standard
I-control	710	714	care
O	715	720	among
B-total-participants	721	724	295
B-eligibility	725	734	survivors
I-eligibility	735	737	of
I-eligibility	738	751	nonmetastatic
I-eligibility	752	758	breast
I-eligibility	759	765	cancer
O	765	766	.

O	767	769	In
O	770	774	this
O	775	779	post
O	780	783	hoc
O	784	792	analysis
O	793	795	of
O	796	800	data
O	801	805	from
O	806	809	the
O	810	818	Physical
O	819	827	Activity
O	828	831	and
O	832	842	Lymphedema
O	843	848	Trial
O	848	849	,
O	850	852	we
O	853	861	examined
O	862	870	incident
O	871	884	deterioration
O	885	887	of
O	888	896	physical
O	897	905	function
O	906	911	after
O	912	914	12
O	915	921	months
O	921	922	,
O	923	930	defined
O	931	933	as
O	934	935	a
O	936	937	â‰¥
O	938	940	10
O	940	941	-
O	941	946	point
O	947	955	decrease
O	956	958	in
O	959	962	the
O	963	971	physical
O	972	980	function
O	981	989	subscale
O	990	992	of
O	993	996	the
O	997	1004	Medical
O	1005	1013	Outcomes
O	1014	1019	Short
O	1019	1020	-
O	1020	1024	Form
O	1025	1027	36
O	1027	1028	-
O	1028	1032	item
O	1033	1046	questionnaire
O	1046	1047	.

O	1048	1051	The
O	1052	1062	proportion
O	1063	1065	of
O	1066	1078	participants
O	1079	1082	who
O	1083	1094	experienced
B-outcome	1095	1103	incident
I-outcome	1104	1112	physical
I-outcome	1113	1121	function
I-outcome	1122	1135	deterioration
I-outcome	1136	1141	after
I-outcome	1142	1144	12
I-outcome	1145	1151	months
O	1152	1155	was
B-cv-bin-percent	1156	1158	16
I-cv-bin-percent	1158	1159	.
I-cv-bin-percent	1159	1160	3
I-cv-bin-percent	1160	1161	%
O	1162	1163	(
B-cv-bin-abs	1163	1165	24
O	1165	1166	/
B-control-participants	1166	1169	147
O	1169	1170	)
O	1171	1173	in
O	1174	1177	the
O	1178	1185	control
O	1186	1191	group
O	1192	1195	and
B-iv-bin-percent	1196	1197	8
I-iv-bin-percent	1197	1198	.
I-iv-bin-percent	1198	1199	1
I-iv-bin-percent	1199	1200	%
O	1201	1202	(
B-iv-bin-abs	1202	1204	12
O	1204	1205	/
B-intervention-participants	1205	1208	148
O	1208	1209	)
O	1210	1212	in
O	1213	1216	the
O	1217	1223	weight
O	1224	1231	lifting
O	1232	1237	group
O	1238	1239	(
O	1239	1247	relative
O	1248	1252	risk
O	1252	1253	,
O	1254	1255	0
O	1255	1256	.
O	1256	1258	49
O	1258	1259	;
O	1260	1262	95
O	1262	1263	%
O	1264	1266	CI
O	1266	1267	,
O	1268	1269	0
O	1269	1270	.
O	1270	1272	25
O	1273	1275	to
O	1276	1277	0
O	1277	1278	.
O	1278	1280	96
O	1280	1281	;
O	1282	1283	P
O	1284	1285	=
O	1286	1287	.
O	1287	1289	04
O	1289	1290	)
O	1290	1291	.

O	1292	1294	No
O	1295	1302	serious
O	1303	1305	or
O	1306	1316	unexpected
B-outcome	1317	1324	adverse
I-outcome	1325	1331	events
O	1332	1340	occurred
O	1341	1345	that
O	1346	1350	were
O	1351	1358	related
O	1359	1361	to
O	1362	1368	weight
O	1369	1376	lifting
O	1376	1377	.

O	1378	1384	Slowly
O	1385	1396	progressive
O	1397	1403	weight
O	1404	1411	lifting
O	1412	1420	compared
O	1421	1425	with
O	1426	1434	standard
O	1435	1439	care
O	1440	1447	reduced
O	1448	1451	the
B-outcome	1452	1461	incidence
I-outcome	1462	1464	of
I-outcome	1465	1473	physical
I-outcome	1474	1482	function
I-outcome	1483	1496	deterioration
O	1497	1502	among
O	1503	1512	survivors
O	1513	1515	of
O	1516	1522	breast
O	1523	1529	cancer
O	1529	1530	.

O	1531	1536	These
O	1537	1541	data
O	1542	1545	are
O	1546	1556	hypothesis
O	1557	1567	generating
O	1567	1568	.

O	1569	1575	Future
O	1576	1583	studies
O	1584	1590	should
O	1591	1599	directly
O	1600	1607	compare
O	1608	1611	the
O	1612	1620	efficacy
O	1621	1623	of
O	1624	1630	weight
O	1631	1638	lifting
O	1639	1643	with
O	1644	1649	other
O	1650	1660	modalities
O	1661	1663	of
O	1664	1672	exercise
O	1672	1673	,
O	1674	1678	such
O	1679	1681	as
O	1682	1687	brisk
O	1688	1695	walking
O	1695	1696	,
O	1697	1699	to
O	1700	1713	appropriately
O	1714	1720	inform
O	1721	1724	the
O	1725	1736	development
O	1737	1739	of
O	1740	1741	a
O	1742	1754	confirmatory
O	1755	1760	study
O	1761	1769	designed
O	1770	1772	to
O	1773	1781	preserve
O	1782	1790	physical
O	1791	1799	function
O	1800	1805	among
O	1806	1815	survivors
O	1816	1818	of
O	1819	1825	breast
O	1826	1832	cancer
O	1832	1833	.
